Edition:
India

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

8,110JPY
21 Oct 2019
Change (% chg)

¥-10 (-0.12%)
Prev Close
¥8,120
Open
¥8,150
Day's High
¥8,200
Day's Low
¥8,060
Volume
52,300
Avg. Vol
91,490
52-wk High
¥8,530
52-wk Low
¥4,260

Latest Key Developments (Source: Significant Developments)

Mesoblast And JCR Pharmaceuticals Expand Japan License Agreement
Tuesday, 11 Jun 2019 

June 11 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>::MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN.MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN.MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN.MESOBLAST LTD - DEAL FOR AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE.MESOBLAST LTD - DEAL FOR JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019.  Full Article

Mesoblast Expands Partnership With JCR Pharmaceuticals
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Mesoblast Ltd ::EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA.  Full Article

JCR Pharmaceuticals initiates phase 3 clinical trial of JR-141 for Hunter Syndrome
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says the company announced today the initiation of a Phase 3 clinical trial of JR-141 in Japan .JR-141 is a blood-brain-barrier (BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR’s proprietary BBB technology, is applied .  Full Article

JCR Pharmaceuticals initiates phase 2 clinical trial of JR-141 for hunter syndrome in Brazil
Friday, 29 Jun 2018 

June 29 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it announced today the initiation of the Phase 2 clinical trial of JR-141 in Brazil.JR-141 is a blood-brain-barrier(BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR's proprietary BBB technology, has been applied .  Full Article

JCR Pharmaceuticals to recall partial sleep apnea alarm products
Monday, 25 Jun 2018 

June 25 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T> ::Says it plans to recall its partial sleep apnea alarm products, which are manufactured by the company and sold by the company and its unit, due to parts' quality problem .  Full Article

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .  Full Article

Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Medipal Holdings Corp <7459.T>:Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd <<<4552.T>>>.Says the JV will be established in January 2018.Says the company and JCR Pharmaceuticals will hold a 35 percent stake and a 65 percent stake in the JV respectively .  Full Article